Founded in 1907 in Vadodara under the patronage of Maharaja Sayajirao Gaekwad, Alembic is one of the oldest Indian pharmaceutical houses, today a roughly ₹6,700 crore Amin-family business combining a branded macrolide anti-infective base with an ANDA-led US generics push.

A Mumbai company that turned a 1953 Patna chemist shop and a 1973 founder bet into India's anti-infective leader, with an ANDA-led US generics business.

A 1978 garage start in Bengaluru on US$10,000 that grew into India's first listed biotech and, through the Biocon Biologics and Syngene franchises, into a globally relevant biosimilars and contract-research platform.

A 1935 Bombay founding by Dr. Khwaja Abdul Hamied that built India's pharmaceutical self-reliance from before Independence, became the global access-to-medicine story under Dr. Yusuf K. Hamied in 2001, and today is a roughly ₹27,500 crore listed pharma anchored by respiratory and chronic-care depth.

An Ahmedabad family-promoted company that compounded a division-led, brand-substitution model across women's healthcare and cardio-diabeto, listing in December 2025.

A 2007 Ahmedabad founding by an ex-Intas executive that built a deliberately India-only branded prescription engine focused on chronic-care specialty therapies, IPO'd in 2017, and is now closing on a ₹3,000 crore run rate.

Founded in 1977 in Ahmedabad by pharmacist Hasmukh Chudgar, Intas is one of India's largest private pharmaceutical companies, anchored by a chronic-care franchise at home and Accord Healthcare's regulated-market generics business in the UK, EU and US.

A Delhi company that scaled a 1995 low-price, rural-first wedge into one of India's largest domestic-formulations franchises, listed in 2023.

India's largest pharmaceutical company, built from a 1983 specialty start into a multi-engine generics, specialty and innovative player.

An Ahmedabad, family-promoted company that grew from a 1959 founder bet into a roughly ₹11,500 crore domestic-led franchise, built as much by acquisition as by launch.

A 1952 Ahmedabad founding that grew from a Patel-Modi partnership into a ₹23,000-plus crore Indian pharma player with a domestic generics base, a biosimilars first mover position (adalimumab Exemptia in 2014) and a growing US specialty pipeline.